Alex Denner (Mark Neuling/CNBC/NBCU Photo Bank via Getty Images)

Ex­clu­sive: Saris­sa's board push drew lit­tle sup­port in Alk­er­mes share­hold­er vote

Saris­sa Cap­i­tal Man­age­ment lost its proxy bat­tle bad­ly against Irish drug­mak­er Alk­er­mes last week, ac­cord­ing to a fi­nal tal­ly of votes for board nom­i­nees.

Saris­sa’s CEO Alex Den­ner re­ceived sup­port from on­ly 24% of the 147 mil­lion shares vot­ed, ac­cord­ing to a com­pa­ny fil­ing re­viewed by End­points News. The in­vest­ment com­pa­ny put up three nom­i­nees to re­place Alk­er­mes board mem­bers, and has waged a long-run­ning cam­paign for changes at the drug com­pa­ny, which Den­ner has called mis­man­aged.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.